Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.
As a writer for Forbes Home since 2021, Emily specializes in writing about home warranties, solar installations, car transportation and moving companies. With a background in journalism and experience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback